A randomized, dose–finding, phase II study of the selective relaxant binding drug, sugammadex, capable of safely reversing profound rocuronium–induced neuromuscular block. - Groudine,SB.; Soto,R.; Lien,C.; Drover,D.; Roberts,K.. (Anesth Analg, 2007)